388 related articles for article (PubMed ID: 26568007)
1. Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma.
Kamide Y; Kaira K; Watanabe T; Kuribayashi S; Ozawa A; Koga Y; Ono A; Sunaga N; Hisada T; Oyama T; Yamada M
Intern Med; 2015; 54(22):2905-9. PubMed ID: 26568007
[TBL] [Abstract][Full Text] [Related]
2. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
3. Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review.
Jing X; Li F; Meng X; Liu Z; Yu J; Liu B
Cancer Biol Ther; 2017 May; 18(5):279-284. PubMed ID: 28362192
[TBL] [Abstract][Full Text] [Related]
4. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
Caumont C; Veillon R; Gros A; Laharanne E; Bégueret H; Merlio JP
Lung Cancer; 2016 Feb; 92():15-8. PubMed ID: 26775590
[TBL] [Abstract][Full Text] [Related]
6. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
[TBL] [Abstract][Full Text] [Related]
7. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
[TBL] [Abstract][Full Text] [Related]
8. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
9. [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
Caliez J; Monnet I; Pujals A; Rousseau-Bussac G; Jabot L; Boudjemaa A; Leroy K; Chouaid C
Rev Mal Respir; 2017 May; 34(5):576-580. PubMed ID: 27646667
[TBL] [Abstract][Full Text] [Related]
10. Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
Cui S; Zhao Y; Dong L; Gu A; Xiong L; Qian J; Zhang W; Niu Y; Pan F; Jiang L
Cancer Med; 2016 Jun; 5(6):1013-21. PubMed ID: 26880708
[TBL] [Abstract][Full Text] [Related]
11. Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report.
Madabhavi I; Patel A; Anand A; Panchal H; Parikh S
Clin Respir J; 2018 Feb; 12(2):806-810. PubMed ID: 27606884
[TBL] [Abstract][Full Text] [Related]
12. Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib.
Nishino M; Sacher AG; Gandhi L; Chen Z; Akbay E; Fedorov A; Westin CF; Hatabu H; Johnson BE; Hammerman P; Wong KK
Eur J Radiol; 2017 Mar; 88():15-20. PubMed ID: 28189201
[TBL] [Abstract][Full Text] [Related]
13. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
14. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
16. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
Levacq D; D'Haene N; de Wind R; Remmelink M; Berghmans T
Lung Cancer; 2016 Dec; 102():38-41. PubMed ID: 27987586
[TBL] [Abstract][Full Text] [Related]
17. Xanthogranulomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer.
Brosseau S; Gounant V; Choudat L; Pluvy J; Zalcman G; Khalil A
Diagn Interv Imaging; 2018 Apr; 99(4):267-268. PubMed ID: 29472032
[No Abstract] [Full Text] [Related]
18. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.
Rosoux A; Pauwels P; Duplaquet F; D'Haene N; Weynand B; Delos M; Menon R; Heukamp LC; Thunnissen E; Ocak S
Lung Cancer; 2016 Aug; 98():118-121. PubMed ID: 27393517
[TBL] [Abstract][Full Text] [Related]
20. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]